NCT04753216View on ClinicalTrials.gov

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

August 31, 2021

Study Completion Date

October 25, 2021

Conditions
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Irinotecan Sucrosofate

Given IV

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER